PortalPublikationenALCAM (CD166) expression and serum levels are markers for po...

ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients

Standard

ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. / Tachezy, Michael; Harms-Effenberger, Katharina; Zander, Hilke; Minner, Sarah Jane Pauline; Gebauer, Florian; Vashist, Yogesh; Sauter, Guido; Pantel, Klaus; Izbicki, Jakob R.; Bockhorn, Maximilian.

in: INT J CANCER, Jahrgang 131, Nr. 2, 2, 15.07.2012, S. 396-405.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Tachezy, M, Harms-Effenberger, K, Zander, H, Minner, SJP, Gebauer, F, Vashist, Y, Sauter, G, Pantel, K, Izbicki, JR & Bockhorn, M 2012, 'ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients', INT J CANCER, Jg. 131, Nr. 2, 2, S. 396-405. https://doi.org/10.1002/ijc.26377

APA

Tachezy, M., Harms-Effenberger, K., Zander, H., Minner, S. J. P., Gebauer, F., Vashist, Y., Sauter, G., Pantel, K., Izbicki, J. R., & Bockhorn, M. (2012). ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. INT J CANCER, 131(2), 396-405. [2]. https://doi.org/10.1002/ijc.26377

Vancouver

Tachezy M, Harms-Effenberger K, Zander H, Minner SJP, Gebauer F, Vashist Y et al. ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. INT J CANCER. 2012 Jul 15;131(2):396-405. 2. https://doi.org/10.1002/ijc.26377

Bibtex

@article{32f01758e78e45b2a625392c47a209de,
title = "ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients",
abstract = "The expression of the activated leukocyte cell adhesion molecule (ALCAM and CD166) is increased in various types of cancer. We aimed to evaluate its role as a prognostic marker for esophageal cancer (EC). We retrospectively analyzed ALCAM expression in 299 primary lesions, 147 lymph node and 46 distant metastases from EC patients, on a tissue microarray using immunohistochemistry. Bone marrow samples from representative cancer patients (n = 16), taken before primary surgery, were stained by double-immunofluorescence for ALCAM and cytokeratins (CK). Blood serum samples from 236 cancer patients and 127 controls were analyzed for serum ALCAM (s-ALCAM) by ELISA. The immunohistochemical analysis showed increased ALCAM expression in the majority of lesions (primary tumor 71%, lymph node 76% and distant metastases 80%). ALCAM expression was not associated with histopathological parameters except for tumor grading (p = 0.015). ALCAM-positive patients had significantly worse recurrence-free and overall survival (OS; p = 0.002). Disseminated tumor cells (DTC) in bone marrow showed two phenotypes, ALCAM+/CK+ (36%) and ALCAM-/CK+ (64%). Multivariate analysis revealed that ALCAM expression and elevated s-ALCAM serum values are powerful prognostic variables for OS in patients with EC (hazard ratio [HR] 3.987, 95% confidence interval [95%CI] 1.906-8.340, p <0.001 and HR 1.915, 95%CI 1.021-3.592, p = 0.043). The results of our study provide preliminary evidence for the potential clinical utility of ALCAM as a prognostic biomarker for EC, which might be a basis for future clinical application. In addition, ALCAM expression in a subset of DTC of the bone marrow indicates a potential function in the metastatic cascade of EC.",
keywords = "Activated-Leukocyte Cell Adhesion Molecule, Adult, Aged, Aged, 80 and over, Esophageal Neoplasms, Female, Humans, Immunohistochemistry, Keratins, Male, Middle Aged, Neoplasm Grading, Prognosis, Protein Array Analysis, Retrospective Studies, Tumor Markers, Biological",
author = "Michael Tachezy and Katharina Harms-Effenberger and Hilke Zander and Minner, {Sarah Jane Pauline} and Florian Gebauer and Yogesh Vashist and Guido Sauter and Klaus Pantel and Izbicki, {Jakob R.} and Maximilian Bockhorn",
note = "Copyright {\textcopyright} 2011 UICC.",
year = "2012",
month = jul,
day = "15",
doi = "10.1002/ijc.26377",
language = "English",
volume = "131",
pages = "396--405",
journal = "INT J CANCER",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients

AU - Tachezy, Michael

AU - Harms-Effenberger, Katharina

AU - Zander, Hilke

AU - Minner, Sarah Jane Pauline

AU - Gebauer, Florian

AU - Vashist, Yogesh

AU - Sauter, Guido

AU - Pantel, Klaus

AU - Izbicki, Jakob R.

AU - Bockhorn, Maximilian

N1 - Copyright © 2011 UICC.

PY - 2012/7/15

Y1 - 2012/7/15

N2 - The expression of the activated leukocyte cell adhesion molecule (ALCAM and CD166) is increased in various types of cancer. We aimed to evaluate its role as a prognostic marker for esophageal cancer (EC). We retrospectively analyzed ALCAM expression in 299 primary lesions, 147 lymph node and 46 distant metastases from EC patients, on a tissue microarray using immunohistochemistry. Bone marrow samples from representative cancer patients (n = 16), taken before primary surgery, were stained by double-immunofluorescence for ALCAM and cytokeratins (CK). Blood serum samples from 236 cancer patients and 127 controls were analyzed for serum ALCAM (s-ALCAM) by ELISA. The immunohistochemical analysis showed increased ALCAM expression in the majority of lesions (primary tumor 71%, lymph node 76% and distant metastases 80%). ALCAM expression was not associated with histopathological parameters except for tumor grading (p = 0.015). ALCAM-positive patients had significantly worse recurrence-free and overall survival (OS; p = 0.002). Disseminated tumor cells (DTC) in bone marrow showed two phenotypes, ALCAM+/CK+ (36%) and ALCAM-/CK+ (64%). Multivariate analysis revealed that ALCAM expression and elevated s-ALCAM serum values are powerful prognostic variables for OS in patients with EC (hazard ratio [HR] 3.987, 95% confidence interval [95%CI] 1.906-8.340, p <0.001 and HR 1.915, 95%CI 1.021-3.592, p = 0.043). The results of our study provide preliminary evidence for the potential clinical utility of ALCAM as a prognostic biomarker for EC, which might be a basis for future clinical application. In addition, ALCAM expression in a subset of DTC of the bone marrow indicates a potential function in the metastatic cascade of EC.

AB - The expression of the activated leukocyte cell adhesion molecule (ALCAM and CD166) is increased in various types of cancer. We aimed to evaluate its role as a prognostic marker for esophageal cancer (EC). We retrospectively analyzed ALCAM expression in 299 primary lesions, 147 lymph node and 46 distant metastases from EC patients, on a tissue microarray using immunohistochemistry. Bone marrow samples from representative cancer patients (n = 16), taken before primary surgery, were stained by double-immunofluorescence for ALCAM and cytokeratins (CK). Blood serum samples from 236 cancer patients and 127 controls were analyzed for serum ALCAM (s-ALCAM) by ELISA. The immunohistochemical analysis showed increased ALCAM expression in the majority of lesions (primary tumor 71%, lymph node 76% and distant metastases 80%). ALCAM expression was not associated with histopathological parameters except for tumor grading (p = 0.015). ALCAM-positive patients had significantly worse recurrence-free and overall survival (OS; p = 0.002). Disseminated tumor cells (DTC) in bone marrow showed two phenotypes, ALCAM+/CK+ (36%) and ALCAM-/CK+ (64%). Multivariate analysis revealed that ALCAM expression and elevated s-ALCAM serum values are powerful prognostic variables for OS in patients with EC (hazard ratio [HR] 3.987, 95% confidence interval [95%CI] 1.906-8.340, p <0.001 and HR 1.915, 95%CI 1.021-3.592, p = 0.043). The results of our study provide preliminary evidence for the potential clinical utility of ALCAM as a prognostic biomarker for EC, which might be a basis for future clinical application. In addition, ALCAM expression in a subset of DTC of the bone marrow indicates a potential function in the metastatic cascade of EC.

KW - Activated-Leukocyte Cell Adhesion Molecule

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Esophageal Neoplasms

KW - Female

KW - Humans

KW - Immunohistochemistry

KW - Keratins

KW - Male

KW - Middle Aged

KW - Neoplasm Grading

KW - Prognosis

KW - Protein Array Analysis

KW - Retrospective Studies

KW - Tumor Markers, Biological

U2 - 10.1002/ijc.26377

DO - 10.1002/ijc.26377

M3 - SCORING: Journal article

C2 - 21858815

VL - 131

SP - 396

EP - 405

JO - INT J CANCER

JF - INT J CANCER

SN - 0020-7136

IS - 2

M1 - 2

ER -